皮肌炎和多发性肌炎相关间质性肺炎的药物治疗

Drug therapy of dermatomyositis/polymyositis-associated interstitial lung disease

间质性肺疾病(ILD)是皮肌炎(DM)和多发性肌炎(PM)常见的并发症,发病率可达35%~40%,其发生机制不明,治疗难度大。本文介绍了DM/PM-ILD常用治疗药物(糖皮质激素、硫唑嘌呤、环磷酰胺、霉酚酸酯和免疫球蛋白)在临床研究中的应用以及新型药物(环孢素A、他克莫司、利妥昔单抗、巴利昔单抗和托法替尼)治疗DM/PM-ILD的研究进展。

Interstitial lung disease(ILD)is a common complication of dermatomyositis(DM)and polymyositis(PM),with the incidence rate of 35%-40%.The nosogenesis of DM/PM-ILD is unclear,and its treatment remains a challenge for clinicians.This review describes the clinical application of commonly-used drugs such as glucocorticoid,azathioprine,cyclophosphamide,mycophenolate mofetil and intravenous immunoglobulin for DM/PM-ILD,and determine the effect of new drugs such as cyclosporin A,tacrolimus,rituximab,tofacitinib,basiliximab,and tofacitinib on DM/PM-ILD.